NCT00321334View on ClinicalTrials.gov

Survival Study of Docetaxel and Carboplatin as Neo-Adjuvant Vs Adjuvant Chemotherapy in Early Stage NSLC

PHASE3CompletedINTERVENTIONAL
Enrollment

410

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Non-small Cell Lung Cancer
Interventions
PROCEDURE

Chemotherapy+Surgery

Docetaxel:75mg/m2 on D1 cycle,3 cycles Carboplatin:AUC=5 on D1 cycle,3 cycles

Trial Locations (1)

510080

Chinese Society of Lung Cancer, Guangzhou

All Listed Sponsors
lead

Chinese Society of Lung Cancer

OTHER

NCT00321334 - Survival Study of Docetaxel and Carboplatin as Neo-Adjuvant Vs Adjuvant Chemotherapy in Early Stage NSLC | Biotech Hunter | Biotech Hunter